ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes wearable robotic exoskeletons for individuals with mobility impairments or other medical conditions in Israel, the United States, Europe, the Asia-Pacific, Latin America, and Africa. It offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for used in the rehabilitation of individuals with lower limb disability due to stroke; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers, institutions, and individuals, as well as through distributors. The company was formerly known as Argo Medical Technologies Ltd. and changed its name to ReWalk Robotics Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.
IPO Year: 2014
Exchange: NASDAQ
Website: rewalk.com
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M
The decision was communicated through CMS' bi-annual Healthcare Common Procedure Coding System ("HCPCS") coding memorandum released yesterday; payment amount determination for ReWalk Personal Exoskeletons will continue to be on a case-by-case basis until such determination is finalized, likely later this year. To date, Lifeward has delivered 35 Personal Exoskeletons to Medicare beneficiaries in an initiative to establish necessary capabilities and processes to support growing demand MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-
Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f
Lifeward brand reflects the Company's commitment to pioneering innovative technology to empower the pursuit of life's ambitions in the face of physical limitation or disability The complete rebrand includes new name, stock ticker, logo, website launch, and corporate messaging MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 29, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk") today unveiled its new corporate branding to officially begin doing business as Lifeward™ ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced today that the Company is expanding its direct sales coverage to Canada. This expansion occurs as the result of the integration between the former ReWalk and AlterG commercial teams following the recent acquisition, which has resulted in a more extensive sales force with increased capacity. "With the formation of our larger, newly combined commercial team, we have expand
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Jan. 11, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company") announced that Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will provide an overview presentation and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 17-18, 2024. The presentation will begin at 2:30 PM EST on January 17, 2024 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_ZpcK-ahiRLabYaQ5ySQKsw. ReWalk will also host virtual one-on-ones with investors on Wednesday and Thursday, January 17-18, 2023. Registrat
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced that it has received payment from Noridian Healthcare Solutions ("Noridian"), a Medicare Administrative Contractor ("MAC"), for its first claim for the ReWalk Personal Exoskeleton. This marks coverage and payment by Medicare fee-for-service for the first-ever claim submitted for a ReWalk Personal Exoskeleton device. This milestone reflects an acknowledgement by Medicare that the Re
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. "Mike brings an extensive background in strategic finance and investor relations
Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 20, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics. Ltd. (NASDAQ:RWLK) ("ReWalk" or "The Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced today that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors, effective today. After initiating his career at McKinsey and Company, Mr. Turk has assembled an extensive history in the medical device industry beginning with his role as Director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including President, where he led all commercialization
HAIFA, Israel, March 23, 2022 /PRNewswire/ -- Tactile Mobility, the leading tactile data and virtual sensing technology company for the automotive industry, municipalities and road authorities, insurance industry, and more, today announced the appointment of Ori Gon as Chief Financial Officer (CFO). With over 10 years in financial operations, Ori will play a key role in the ongoing development of Tactile Mobility's strategy, creating the infrastructure for future funding activities and facilitating the company's rapid growth and expansion. "We are thrilled to welcome Ori to our team during this critical time in Tactile Mobility's development," said Shahar Bin-Nun, CEO of Tactile Mobility. "O
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
MARLBOROUGH, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced Jeannine Lynch will join the Company on August 31, 2021, as Vice President of Strategy and Market Access. Ms. Lynch will focus on completing the building and implementation of ReWalk's market access and reimbursement programs. Ms. Lynch will report to ReWalk CEO, Larry Jasinski. She will also be part of the management team responsible for overseeing planning and implementation of all company business strategy and policies. "We have been the worldwide leader in building p
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
DEFA14A - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
10-Q - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13G/A - ReWalk Robotics Ltd. (0001607962) (Subject)
ReWalk Robotics, Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced the successful demonstration of a proof-of-concept next-generation exoskeleton. As part of the Israel Innovation Authority's MAGNET incentive program, the Human Robot Interaction Consortium (the "HRI Consortium"), the company has reached a milestone by integrating advanced sensing technologies and artificial intelligence ("AI") to enable autonomous decision making in the Company's latest exoskeleton prototype. "We have successfully demonstrated that by combining
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ReWalk Robotics (NASDAQ:RWLK) with a Buy and maintains $3 price target.
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its third quarter. • Argo Blockchain (NASDAQ:ARBK) is estimated to report quarterly loss at $0.12 per share on revenue of $13.28 million. • SuperCom (NASDAQ:SPCB) is estimated to report quarterly earnings at $0.00 per share on revenue of $4.60 million. • Moving iMage Technologies (AMEX:MITQ) is projected to report earnings for its first quarter. • Eagle Pharmaceuticals (NASDAQ:EGRX) is likely to report quarterly earnings at $1.06 per share on revenue of $62.60 million. • 2sevent
`
ReWalk Robotics (NASDAQ:RWLK) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here's what investors need to know before the announcement. Analysts estimate that ReWalk Robotics will report an earnings per share (EPS) of $-0.11. ReWalk Robotics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.01, which was followed by a 0.0% drop
The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. VolitionRx The Trade: VolitionRx Limited (NYSE:VNRX) Director Phillip Barnes acquired a total of 5,000 shares an average price of $1.30. To acquire these shares, it cost around $6,500. What’s Happening: VolitionRX posted a narrower-than-expected qu
The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. BioRestorative Therapies The Trade: BioRestorative Therapies, Inc. (NASDAQ:BRTX) Director, VP of Research and Development Francisco Silva acquired a total of 4,954 shares an average price of $2.22. To acquire these shares, it cost around $10,998. What
The Dow Jones closed higher by around 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Lulu's Fashion Lounge Holdings The Trade: Lulu's Fashion Lounge Holdings, Inc. (NASDAQ:LVLU) Director Michael J Mardy acquired a total of 10,000 shares an average price of $2.10. To acquire these shares, it cost around $21,000. What’s Happening: Lulu
Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f
Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN and YOKNEAM ILLIT, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and nine months ended September 30, 2023. Highlights of the Third Quarter of 2023 include: Closing of ReWalk's acquisition o
MARLBOROUGH, Mass., and BERLIN, and YOKNEAM ILLIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced that that it has scheduled a conference call for Wednesday, November 8, 2023 at 8:30 a.m. EST, to discuss Medicare's preliminary payment determination for the ReWalk Personal Exoskeleton. On Friday, November 3, the Centers for Medicare & Medicaid Services ("CMS") released an agenda for the upcoming Healthcare Common Procedure Coding System ("HCPCS") meeting on
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company") today announced that the Company will release its third quarter 2023 financial results on Tuesday, November 14, 2023, prior to the U.S. financial markets open. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (U.S)1-412-317-0690Germany0800-6647650Israel1-809-212373Access CodePlease reference the
Revenue in Line with Prior Financial Guidance Continued Progress with CMS in Establishment of Medicare Benefit Category for Exoskeletons Pending Acquisition of AlterG Expected to Contribute to ReWalk Financial Results Starting in Q3'23 MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Aug. 11, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and six months ended June 30, 2023. Highlights of the Second Quarter of 2023 include: Total
Combined Company Expands Patient and Clinician Access to Innovative Rehabilitation Technologies for Home and Clinic Use Transaction Projected to Increase Revenue Growth and Improve Operating Margin, While Reducing Cash Burn Rate MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Aug. 08, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced the execution of a definitive agreement to acquire AlterG, Inc. ("AlterG"), a leading innovator and provider of Anti-Gravity systems for use in physical a
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company") announced that the Company will release its second quarter 2023 financial results before the markets open on Friday, August 11, 2023. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (U.S)1-412-317-0690Germany0800-6647650Israel1-80-9212373Access CodePlease reference the "ReWalk Robotics Ltd. Ca
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 05, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or "the Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced that it will host a conference call and webcast on Tuesday, July 11, 2023 to discuss the recent proposal from the Centers for Medicare & Medicaid Services ("CMS") to include personal exoskeletons in the Medicare benefit category for braces as part of the Calendar Year 2024 Home Health Prospective Payment System Proposed Rule, CMS-1780-P ("Proposed Rule"), released on June 30, 2023.
On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN and YOKNEAM ILLIT, Israel, May 11, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three months ended March 31, 2023. Highlights of the first quarter of 2023 include: Total revenue for the first quarter of 2023 was $1.2 million, as compared to $0.9 million in the first quarter of 2022, up 40%;Gross margin was 46.4%